VIGOR Study Design Relevance of the 50 mg Dose
“Dose-creep” phenomenon in chronic painful conditions
Rofecoxib 50 mg dose is approved for the treatment of acute pain
Post-marketing usage data
Previous slide
Next slide
Back to first slide
View graphic version